Hyperuricemia and the Prognosis of Hypertensive Patients: A Systematic Review and Meta-Analysis

Overview

Journal J Clin Hypertens (Greenwich)

Specialty Cardiology & Vascular Diseases

Date 2016 Jun 2

PMID 27247021

Citations 15

Authors

Tianqiang Qin

Xiaoqin Zhou

Ji Wang

Xinyu Wu

Yulin Li

Ling Wang

He Huang

Jing Li

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to assess the prognostic value of hyperuricemia in patients with established hypertension by systematic review and meta-analysis of cohort studies. MEDLINE, Embase, and the Chinese Biomedical Literature Database were searched through January 2015. Seventeen cohort studies were included and their methodological quality was moderate to high, with Newcastle-Ottawa Scale scores ranging from 6 to 9. Random-effects model meta-analyses showed that in terms of adjusted categorical data, hyperuricemia significantly correlated with cardiovascular diseases in hypertensive patients (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.13-2.03), all-cause mortality (HR, 1.12; 95%CI, 1.02-1.23), and diabetes (HR, 1.84; 95% CI, 1.02-3.30) but not with stroke (HR, 0.85; 95%CI, 0.57-1.27); while, in terms of adjusted continuous data, the corresponding pooled HRs were 1.17 (95% CI, 1.07-1.27), 1.05 (95% CI, 0.98-1.13), 1.28 (95% CI, 1.18-1.38), and 1.06 (95% CI, 0.98-1.16), respectively. The findings of our meta-analysis suggest that hyperuricemia could slightly increase the risk of cardiovascular diseases and diabetes in patients with hypertension.

Citing Articles

Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan　- A JMDC Claims Database Study.

Kario K, Akari S, Kanegae H Circ Rep. 2025; 7(3):183-190.

PMID: 40066219 PMC: 11890272. DOI: 10.1253/circrep.CR-24-0178.

Potential of traditional Chinese medicine lyophilized powder of in the treatment of hyperuricemia.

Huang K, Chen H, Lin J World J Clin Cases. 2024; 12(36):6939-6943.

PMID: 39726925 PMC: 11531976. DOI: 10.12998/wjcc.v12.i36.6939.

Allopurinol for Secondary Prevention in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Ye Y, Liao G, Liu T, Hu X, Chen X, Bai L J Cardiovasc Dev Dis. 2023; 10(9).

PMID: 37754808 PMC: 10532321. DOI: 10.3390/jcdd10090379.

The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.

Akari S, Nakamura T, Furusawa K, Miyazaki Y, Kario K J Clin Hypertens (Greenwich). 2022; 24(8):1068-1075.

PMID: 35818841 PMC: 9380143. DOI: 10.1111/jch.14539.

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.

Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P BMC Nephrol. 2022; 23(1):223.

PMID: 35739495 PMC: 9229855. DOI: 10.1186/s12882-022-02850-3.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Hare J, Johnson R . Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003; 107(15):1951-3. DOI: 10.1161/01.CIR.0000066420.36123.35. View

Corry D, Eslami P, Yamamoto K, Nyby M, Makino H, Tuck M . Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008; 26(2):269-75. DOI: 10.1097/HJH.0b013e3282f240bf. View

Feig D, Kang D, Johnson R . Uric acid and cardiovascular risk. N Engl J Med. 2008; 359(17):1811-21. PMC: 2684330. DOI: 10.1056/NEJMra0800885. View

. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up program, stratified by other risk factors. The Hypertension Detection and Follow-up Program Cooperative Research Group. Prev Med. 1985; 14(3):312-35. DOI: 10.1016/0091-7435(85)90059-3. View

Kawai T, Ohishi M, Takeya Y, Onishi M, Ito N, Yamamoto K . Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients. Hypertens Res. 2012; 35(11):1087-92. DOI: 10.1038/hr.2012.99. View

Tofuku Y, Kuroda M, Takeda R . Hyperuricemia associated with hypertension. A 4-year follow-up study of hyperuricemic hypertensives. Jpn Circ J. 1978; 42(7):871-9. DOI: 10.1253/jcj.42.871. View

Alderman M, Cohen H, Madhavan S, Kivlighn S . Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999; 34(1):144-50. DOI: 10.1161/01.hyp.34.1.144. View

Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y . Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension. 2005; 47(2):195-202. DOI: 10.1161/01.HYP.0000200033.14574.14. View

10.

Dawson J, Jeemon P, Hetherington L, Judd C, Hastie C, Schulz C . Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension. 2013; 62(1):105-11. DOI: 10.1161/HYPERTENSIONAHA.113.00859. View

11.

Vaduganathan M, Greene S, Ambrosy A, Mentz R, Subacius H, Chioncel O . Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol. 2014; 114(11):1713-21. DOI: 10.1016/j.amjcard.2014.09.008. View

12.

Grayson P, Kim S, LaValley M, Choi H . Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010; 63(1):102-10. PMC: 3016454. DOI: 10.1002/acr.20344. View

13.

Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E . Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45(5):991-6. DOI: 10.1161/01.HYP.0000161184.10873.ea. View

14.

Freedman D, Williamson D, Gunter E, Byers T . Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995; 141(7):637-44. DOI: 10.1093/oxfordjournals.aje.a117479. View

15.

Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P . Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000; 36(6):1072-8. DOI: 10.1161/01.hyp.36.6.1072. View

16.

Wiik B, Larstorp A, Hoieggen A, Kjeldsen S, Olsen M, Ibsen H . Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Am J Hypertens. 2010; 23(8):845-51. DOI: 10.1038/ajh.2010.89. View

17.

Bose B, Badve S, Hiremath S, Boudville N, Brown F, Cass A . Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2013; 29(2):406-13. DOI: 10.1093/ndt/gft378. View

18.

Zhang Y, He F, Ding H, Dai W, Zhang Q, Luan H . Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(4):476-481. DOI: 10.1007/s11596-014-1302-4. View

19.

Mazzali M, Hughes J, Kim Y, Jefferson J, Kang D, Gordon K . Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38(5):1101-6. DOI: 10.1161/hy1101.092839. View

20.

MacIsaac R, Salatzki J, Higgins P, Walters M, Padmanabhan S, Dominiczak A . Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension. 2016; 67(3):535-40. DOI: 10.1161/HYPERTENSIONAHA.115.06344. View